Publication|Articles|December 2, 2025
Supplements and Featured Publications
- The Transformative Approach of TEVIMBRA® (tislelizumab-jsgr) in Managing ESCC and GC/GEJC
The Transformative Approach of TEVIMBRA® (tislelizumab-jsgr) in Managing ESCC and GC/GEJC
Advertisement
This Clinical Brief was sponsored by BeOne Medicines.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA to Accept Deidentified Real-World Evidence for Select Medical Device Applications
2
FDA Approves Fam-Trastuzumab Deruxtecan-Nxki for Metastatic HER2-Positive Breast Cancer
3
COVID-19 Vaccination in Pregnant Patients Reduces Hospitalization, Preterm Birth Across Variants
4
ACA Subsidy Expiration Raises Concerns for Behavioral Health Access and ED Strain
5





































